AUNA Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 4.74% compared to Auna SA's net margin of 0.11%. Auna SA's return on equity of 11.53% beat Astrana Health, Inc.'s return on equity of 1.85%.

Auna SA has a consensus price target of $10.42, signalling upside risk potential of 111.72%. On the other hand Astrana Health, Inc. has an analysts' consensus of $37.6667 which suggests that it could grow by 51.82%. Given that Auna SA has higher upside potential than Astrana Health, Inc., analysts believe Auna SA is more attractive than Astrana Health, Inc..

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Auna SA quarterly revenues are $316.1M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Auna SA's net income of $15M is higher than Astrana Health, Inc.'s net income of $1.1M. Notably, Auna SA's price-to-earnings ratio is 7.12x while Astrana Health, Inc.'s PE ratio is 130.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.31x versus 0.42x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eurofins Scientific SE has a net margin of 4.74% compared to Auna SA's net margin of --. Auna SA's return on equity of 11.53% beat Eurofins Scientific SE's return on equity of 8.55%.

Auna SA has a consensus price target of $10.42, signalling upside risk potential of 111.72%. On the other hand Eurofins Scientific SE has an analysts' consensus of -- which suggests that it could fall by --. Given that Auna SA has higher upside potential than Eurofins Scientific SE, analysts believe Auna SA is more attractive than Eurofins Scientific SE.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eurofins Scientific SE has a beta of 0.631, suggesting its less volatile than the S&P 500 by 36.887%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eurofins Scientific SE offers a yield of 1.66% to investors and pays a quarterly dividend of $0.68 per share. Auna SA pays -- of its earnings as a dividend. Eurofins Scientific SE pays out 28.14% of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Auna SA quarterly revenues are $316.1M, which are larger than Eurofins Scientific SE quarterly revenues of --. Auna SA's net income of $15M is higher than Eurofins Scientific SE's net income of --. Notably, Auna SA's price-to-earnings ratio is 7.12x while Eurofins Scientific SE's PE ratio is 29.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.31x versus 1.80x for Eurofins Scientific SE. Usually stocks with elevated PS ratios are considered overvalued.

Moolec Science SA has a net margin of 4.74% compared to Auna SA's net margin of -166.47%. Auna SA's return on equity of 11.53% beat Moolec Science SA's return on equity of -93.42%.

Auna SA has a consensus price target of $10.42, signalling upside risk potential of 111.72%. On the other hand Moolec Science SA has an analysts' consensus of -- which suggests that it could grow by 11683.19%. Given that Moolec Science SA has higher upside potential than Auna SA, analysts believe Moolec Science SA is more attractive than Auna SA.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moolec Science SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moolec Science SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays -- of its earnings as a dividend. Moolec Science SA pays out -- of its earnings as a dividend.

Auna SA quarterly revenues are $316.1M, which are larger than Moolec Science SA quarterly revenues of $1.5M. Auna SA's net income of $15M is higher than Moolec Science SA's net income of -$2.5M. Notably, Auna SA's price-to-earnings ratio is 7.12x while Moolec Science SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.31x versus 0.97x for Moolec Science SA. Usually stocks with elevated PS ratios are considered overvalued.

Sofgen Pharma SA has a net margin of 4.74% compared to Auna SA's net margin of --. Auna SA's return on equity of 11.53% beat Sofgen Pharma SA's return on equity of --.

Auna SA has a consensus price target of $10.42, signalling upside risk potential of 111.72%. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 19820.32%. Given that Sofgen Pharma SA has higher upside potential than Auna SA, analysts believe Sofgen Pharma SA is more attractive than Auna SA.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 62.945, suggesting its more volatile than the S&P 500 by 6194.533%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays -- of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend.

Auna SA quarterly revenues are $316.1M, which are larger than Sofgen Pharma SA quarterly revenues of --. Auna SA's net income of $15M is higher than Sofgen Pharma SA's net income of --. Notably, Auna SA's price-to-earnings ratio is 7.12x while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.31x versus 0.01x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.